October 28, 2018 | Joanne Morrison
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
Wednesday, April 05, 2023
UM School of Medicine Researchers Chart Path Forward on Developing mRNA Vaccines for Infections Beyond COVID-19
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza. Last month, UMSOM faculty in the Center for Vaccine Development and Global Health (CVD) launched a new clinical trial to investigate the use of mRNA technologies to create a vaccine against malaria. CVD Director Kathleen M. Neuzil, MD, MPH, FIDSA also provided commentary in the nation’s leading medical journal on the feasibility of using mRNA to develop a universal influenza vaccine that could eliminate the need for seasonal shots.
Thursday, December 22, 2022
A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria. That is the finding of a new study published Dec. 7 in Science Translational Medicine. Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) led the work.
Monday, July 18, 2022
New Genomic Research Shows Why Testing Malaria Vaccines in the Clinic is as Rigorous as Natural Exposure in the Field
Malaria is the deadliest mosquito-borne parasitic infection of humans. In 2021, after a century of research, the World Health Organization (WHO) approved the world’s first malaria vaccine. That vaccine reduces the incidence of malaria infections in young children aged 5-17 months by only 30 percent, meaning that it remains critical to continue developing and testing more effective vaccines.
Wednesday, January 26, 2022
Trial Co-led by University of Maryland School of Medicine Scientist Confirms Safety of “Mix-and-Match” COVID-19 Vaccine Booster Dosing
A University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), expert is co-leading an ongoing study that was pivotal in recommending adults and teens receive booster COVID-19 shots of their choosing starting in fall 2021. The preliminary clinical trial results, reported today in The New England Journal of Medicine, found that is safe and effective to receive boosters that are the same or a different one from the person’s primary vaccine(s).
Tuesday, November 02, 2021
Malaria, a pathogen transmitted into blood by mosquitoes in tropical climates, is typically thought of as a blood and liver infection. However, in a newly published study, researchers at the University of Maryland School of Medicine (UMSOM) have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as the lungs, intestines, or vagina — in study participants with malaria.
Wednesday, August 05, 2020
UMSOM Acclaimed Physician-Scientist and Student Mentor, Dr. Miriam Laufer, to Join Academic Affairs Leadership Team as Assistant Dean for Medical Student Research Education
University of Maryland School of Medicine (UMSOM) Vice Dean for Academic Affairs, James Kaper, PhD, along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced that Miriam Laufer, MD, MPH, Professor of Pediatrics and Associate Director of the Center for Vaccine Development and Global Health (CVD), will join the Academic Affairs leadership team as Assistant Dean for Medical Student Research Education.
Wednesday, October 30, 2019
UM School of Medicine's Myron M. Levine, MD, DTPH, to Receive Prestigious Lifetime Award for Five Decades of Pioneering Vaccine Research
Myron M. Levine, MD, DTPH, the Simon and Bessie Grollman Distinguished Professor at the University of Maryland School of Medicine (UMSOM), Associate Dean for Global Health, Vaccinology and Infectious Diseases, and Founder and Former Director of the Center for Vaccine Development and Global Health (CVD) is a co-recipient of the 2020 Research! America Geoffrey Beene Foundation Builders of Science Award for his pioneering vaccine and infectious disease research.
Monday, October 21, 2019
UM School of Medicine's Kathleen M Neuzil Elected as Member of Prestigious National Academy of Medicine
Kathleen M. Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been elected as a member of the National Academy of Medicine (NAM), in recognition of her pivotal research that has informed and shaped global vaccine and public health policy. Her membership was announced at the annual NAM meeting in Washington, D.C., placing her among the 2,178 U.S. members of this important organization. Membership in the Academy is considered one of the highest honors for individuals who have made major contributions to the advancement of the medical sciences, health care and public health.
Monday, August 19, 2019
Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).
Wednesday, July 17, 2019
Vaccines Tested in UM School of Medicine’s Center for Vaccine Development Protect Children Around the World
For 30 years, the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) has collaborated with the Pediatric Center of Frederick to test vaccines used in pediatric care.
Friday, March 08, 2019
UMSOM Researchers Unveil Progress and Challenges in Introducing Typhoid Conjugate Vaccine in Sub-Saharan Africa and Asia
Each year there are nearly 11 million cases of typhoid, a disease that is spread through contaminated food, drink and water. Researchers at the University of Maryland School of Medicine are leading an international consortium that is studying the impact of a typhoid conjugate vaccine (TCV) in an effort to accelerate introduction of the vaccine in countries in sub-Saharan Africa and Asia where there is a high burden of typhoid.
Wednesday, December 26, 2018
Multicenter Trial Supports Use of Topical Antibiotic as a Tool to Eliminate Staph Colonization in NICU Babies
A team of doctors led by Karen L. Kotloff, M.D., University of Maryland School of Medicine (UMSOM), Center for Vaccine Development and Global Health (CVD), has performed a clinical trial involving multiple hospitals that tested the effectiveness of applying a topical antibiotic known as mupirocin for prevention of Staphylococcus aureus (SA) infection in babies in the neonatal intensive care unit (NICU). This study was published in the journal Pediatrics.
Thursday, December 20, 2018
Data collected from the Global Enteric Multicenter Study (GEMS), a multi-site research project studying diarrheal diseases that was designed and coordinated by researchers in the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), are now available to scientists on two online data resources.
Monday, December 03, 2018
UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa
A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.
Friday, November 02, 2018
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.
Wednesday, June 06, 2018
In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others.
Tuesday, May 15, 2018
Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults.
Thursday, May 04, 2017
The University of Maryland School of Medicine has been awarded an International Center of Excellence for Malaria Research (ICEMR) grant by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), one of seven ICEMRs awarded worldwide. With funding of more than $9 million over seven years, the grant will be used to research and develop new tools to help eliminate drug-resistant malaria in Myanmar and neighboring countries in Southeast Asia.
Friday, February 24, 2017
Experimental Malaria Vaccine Provides Durable Protection Against Multiple Strains in NIH Clinical Trial
An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published this week in the Proceedings of the National Academy of Sciences (PNAS). The research was conducted by scientists at the University of Maryland School of Medicine and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Wednesday, July 06, 2016
Malaria is one of the world’s deadliest diseases: it infects hundreds of millions of people every year, and kills about half a million, most of them under five years of age.